215 related articles for article (PubMed ID: 27221978)
1. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart.
Huang XP; Ludke A; Dhingra S; Guo J; Sun Z; Zhang L; Weisel RD; Li RK
FASEB J; 2016 Sep; 30(9):3069-82. PubMed ID: 27221978
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-induced increase in Sug1 leads to poor post-transplantation survival of allogeneic mesenchymal stem cells.
Abu-El-Rub E; Sareen N; Lester Sequiera G; Ammar HI; Yan W; ShamsEldeen AM; Rubinchik I; Moudgil M; Shokry HS; Rashed LA; Dhingra S
FASEB J; 2020 Sep; 34(9):12860-12876. PubMed ID: 32770803
[TBL] [Abstract][Full Text] [Related]
3. Prolonged survival of class II transactivator-deficient cardiac allografts.
June Brickey W; Felix NJ; Griffiths R; Zhang J; Wang B; Piskurich JF; Itoh-Lindstrom Y; Coffman TM; Ting JP
Transplantation; 2002 Nov; 74(9):1341-8. PubMed ID: 12451276
[TBL] [Abstract][Full Text] [Related]
4. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
[TBL] [Abstract][Full Text] [Related]
5. Delayed allograft rejection by the suppression of class II transactivator.
Kim TW; Choi YM; Seo JN; Kim JH; Suh YH; Chung DH; Jung KC; Oh KI
Exp Mol Med; 2006 Jun; 38(3):210-6. PubMed ID: 16819279
[TBL] [Abstract][Full Text] [Related]
6. [Major histocompatibility complex class II transactivator (CIITA) hammer- head ribozyme transfer inhibits major histocompatibility complex class II (MHC-II) expression in Jukart cells].
Guo R; Zou P; Song YP; Ma J; Lu HZ; Cao YL; Tong YJ
Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):925-8. PubMed ID: 14723817
[TBL] [Abstract][Full Text] [Related]
7. Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis.
Waldburger JM; Palmer G; Seemayer C; Lamacchia C; Finckh A; Christofilopoulos P; Baeten D; Reith W; Gabay C
Arthritis Rheum; 2011 Nov; 63(11):3354-63. PubMed ID: 21739421
[TBL] [Abstract][Full Text] [Related]
8. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
[TBL] [Abstract][Full Text] [Related]
9. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
Broxmeyer HE; Cooper S; Hangoc G; Chang CH
Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
[TBL] [Abstract][Full Text] [Related]
10. Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells.
Kitamura N; Yokoyama H; Yashiro T; Nakano N; Nishiyama M; Kanada S; Fukai T; Hara M; Ikeda S; Ogawa H; Okumura K; Nishiyama C
J Allergy Clin Immunol; 2012 Mar; 129(3):814-824.e6. PubMed ID: 22112519
[TBL] [Abstract][Full Text] [Related]
11. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
[TBL] [Abstract][Full Text] [Related]
12. Imaging the survival and utility of pre-differentiated allogeneic MSC in ischemic heart.
Xia C; Cao J
Biochem Biophys Res Commun; 2013 Aug; 438(2):382-7. PubMed ID: 23899528
[TBL] [Abstract][Full Text] [Related]
13. The role of the class II transactivator (CIITA) in MHC class I and II regulation and graft rejection in kidney.
Sims TN; Afrouzian M; Urmson J; Zhu LF; Halloran PF
Am J Transplant; 2001 Sep; 1(3):211-21. PubMed ID: 12102254
[TBL] [Abstract][Full Text] [Related]
14. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in myelomonocytic cells.
De Lerma Barbaro A; Procopio FA; Mortara L; Tosi G; Accolla RS
Eur J Immunol; 2005 Feb; 35(2):603-11. PubMed ID: 15627980
[TBL] [Abstract][Full Text] [Related]
15. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of MHC II in mesenchymal stem cells at high IFN-gamma can be partly explained by cytoplasmic retention of CIITA.
Tang KC; Trzaska KA; Smirnov SV; Kotenko SV; Schwander SK; Ellner JJ; Rameshwar P
J Immunol; 2008 Feb; 180(3):1826-33. PubMed ID: 18209080
[TBL] [Abstract][Full Text] [Related]
17. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
18. Preserving prostaglandin E2 level prevents rejection of implanted allogeneic mesenchymal stem cells and restores postinfarction ventricular function.
Dhingra S; Li P; Huang XP; Guo J; Wu J; Mihic A; Li SH; Zang WF; Shen D; Weisel RD; Singal PK; Li RK
Circulation; 2013 Sep; 128(11 Suppl 1):S69-78. PubMed ID: 24030423
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the specificity of the MHC class II transactivator CIITA in vivo.
Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W
Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565
[TBL] [Abstract][Full Text] [Related]
20. Repression of allo-cell transplant rejection through CIITA ribonuclease P+ hepatocyte.
Guo R; Zou P; Fan HH; Gao F; Shang QX; Cao YL; Lu HZ
World J Gastroenterol; 2003 May; 9(5):1077-81. PubMed ID: 12717860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
